Assembly Biosciences, Inc. (ASMB)
ASMB Stock Price Chart
Explore Assembly Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze ASMB price movements and trends.
ASMB Company Profile
Discover essential business fundamentals and corporate details for Assembly Biosciences, Inc. (ASMB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Dec 2010
Employees
73.00
Website
https://www.assemblybio.comCEO
Jason A. Okazaki
Description
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
ASMB Financial Timeline
Browse a chronological timeline of Assembly Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.70, while revenue estimate is $8.60m.
Earnings released on 7 May 2026
EPS came in at -$0.54 surpassing the estimated -$0.73 by +26.03%, while revenue for the quarter reached $8.21m , missing expectations by -11.36%.
Earnings released on 19 Mar 2026
EPS came in at $2.48 surpassing the estimated -$0.51 by +586.27%, while revenue for the quarter reached $42.46m , beating expectations by +472.24%.
Earnings released on 10 Nov 2025
EPS came in at -$0.72 falling short of the estimated -$0.50 by -44.00%, while revenue for the quarter reached $10.79m , beating expectations by +44.64%.
Earnings released on 6 Aug 2025
EPS came in at -$1.33 falling short of the estimated -$0.65 by -103.57%, while revenue for the quarter reached $9.63m , beating expectations by +3.24%.
Earnings released on 8 May 2025
EPS came in at -$1.17 surpassing the estimated -$2.01 by +41.79%, while revenue for the quarter reached $9.42m , beating expectations by +27.03%.
Earnings released on 20 Mar 2025
EPS came in at -$1.57 surpassing the estimated -$1.75 by +10.29%, while revenue for the quarter reached $7.36m , beating expectations by +107.24%.
Earnings released on 7 Nov 2024
EPS came in at -$1.51 surpassing the estimated -$2.02 by +25.25%, while revenue for the quarter reached $6.85m , missing expectations by -2.91%.
Earnings released on 8 Aug 2024
EPS came in at -$1.98 surpassing the estimated -$2.96 by +33.11%, while revenue for the quarter reached $8.53m , beating expectations by +43.17%.
Earnings released on 8 May 2024
EPS came in at -$1.66 surpassing the estimated -$2.74 by +39.42%, while revenue for the quarter reached $5.79m .
Earnings released on 27 Mar 2024
EPS came in at -$2.15 surpassing the estimated -$2.88 by +25.35%, while revenue for the quarter reached $7.16m .
Stock split effective on 12 Feb 2024
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Nov 2023
EPS came in at -$3.24 falling short of the estimated -$2.76 by -17.39%.
Earnings released on 9 Aug 2023
EPS came in at -$3.84 falling short of the estimated -$3.48 by -10.34%.
Earnings released on 4 May 2023
EPS came in at -$4.44 matching the estimated -$4.44.
Earnings released on 22 Mar 2023
EPS came in at -$5.52 surpassing the estimated -$6.72 by +17.86%.
Earnings released on 8 Nov 2022
EPS came in at -$5.76 falling short of the estimated -$5.64 by -2.13%.
Earnings released on 9 Aug 2022
EPS came in at -$6.12 falling short of the estimated -$5.88 by -4.08%.
Earnings released on 12 May 2022
EPS came in at -$5.76 surpassing the estimated -$5.88 by +2.04%.
Earnings released on 10 Mar 2022
EPS came in at -$4.92 surpassing the estimated -$6.00 by +18.00%.
Earnings released on 4 Nov 2021
EPS came in at -$4.92 surpassing the estimated -$6.60 by +25.45%, while revenue for the quarter reached $6.25m , missing expectations by -20.29%.
Earnings released on 5 Aug 2021
EPS came in at -$6.60 surpassing the estimated -$7.68 by +14.06%.
ASMB Stock Performance
Access detailed ASMB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
